Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America ...Middle East

STOCKHOLM, Oct. 6, 2023 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and...

Hence then, the article about moberg pharma has completed enrollment to the phase 3 study for mob 015 in north america was published today ( Friday 06/10/2023 - 09:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America )

Also on site :

• US lawmakers demand answers from Instructure after Canvas data breaches .. TechCrunch
• In wild late-night posting spree, Trump attacks Obama with imaginary quote and false conspiracy theories
• Encrypted texts reveal how Nvidia chips and U.S. tech are being smuggled to China and Russia